Many agents are in ongoing trials, and may provide additional options for patients with metastatic HER2-positive disease.
Lack of research data and failure to consider patients' functional age affects how older adults with breast cancer are managed.
Differences between the sexes are known in a variety of cancers, but the reasons remain unclear.
CTA spoke with Judith A. Paice, PhD, RN, to better understand how clinicians are reacting to these legalizations and how she responds to patients asking about cannabis use.
Watson, hoped to be a major source for clinicians, is limited by an inability to interpret clinical trials.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Watson: A Glorified Search Engine?
- Seven States Pass Some Form of Marijuana Legalization
- Nivolumab + Ibrutinib Active in Relapsed/Refractory CLL and Richter Transformation
- Study Identifies Ultra-high Risk Category of Patients With DLBCL
- Chemo-free Induction Efficacious in Younger Patients With Mantle Cell Lymphoma
- Non-Hodgkin Lymphoma (NHL) Treatment Regimens: Diffuse Large B-Cell Lymphoma
- Head and Neck Cancers Treatment Regimens
- Renal Cell Carcinoma Treatment Regimens
- Esophageal and Esophagogastric Junction Cancer Treatment Regimens
- Model Predicts That Healthful Lifestyle Benefits Women at Risk of Breast Cancer
- Extending Adjuvant Anastrozole to 6 Years After Tamoxifen Does Not Improve Breast Cancer Survival
- Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLC
- Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients with NSCLC
- Tobacco Companies Seeking to Influence Policy Are Violating the Framework Convention on Tobacco Control
- Pembrolizumab Improves QOL Compared to Chemotherapy in NSCLC